Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer

Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Michael Krainer(Medical University of Vienna), Yohann Loriot(Institut Gustave Roussy), Lorraine Creppy, Steinbjørn Hansen, Jean‐Pascal Machiels(Cliniques Universitaires Saint-Luc), Gero Kramer(Memorial Sloan Kettering Cancer Center), M. Holmberg, F. Rolland(Institut de Cancérologie de l'Ouest), Orazio Caffo(Ospedale Santa Chiara)
Digital Access to Libraries
January 1, 2015
10.1111/bju.12845
Cited by 4

Related Papers

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k